Aparna R. Parikh, MD

Articles

Dr Parikh on Currently Available Targeted Treatment Approaches for Mutated CRC

October 29th 2024

Aparna Parikh, MD, discusses currently available targeted therapy options for patients with colorectal cancer.

Key Takeaways and Closing Thoughts on ADCs

August 29th 2024

Experts discuss key takeaways and closing thoughts on antibody-drug conjugates (ADCs) in cancer treatment.

Emerging ADCs in Development

August 22nd 2024

Key opinion leaders examine promising antibody-drug conjugates (ADCs) in the pharmaceutical development pipeline.

ADC Sequencing

August 22nd 2024

Expert clinicians offer strategic guidance on optimal sequencing of antibody-drug conjugates (ADCs) in treatment protocols.

Dr Parikh on the Rationale for Adding ERAS-007 to the BEACON Regimen in BRAF V600E–Mutant mCRC

August 21st 2024

Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Management of Emetogenicity of Antibody-Drug Conjugates

August 15th 2024

Experts provide clinical insights on the management of emetogenicity in patients receiving antibody-drug conjugates.

Managing Hematologic AEs Associated with ADC Treatments

August 15th 2024

A panel of experts discuss hematologic adverse events associated with antibody-drug conjugate therapies.

Managing Toxicities in Short- and Long-Term Treatment with ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses short-term and long-term treatments with ADCs.

Managing ILD and Pneumonitis Risk From ADCs

August 8th 2024

Vijayakrishna Gadi, MD, PhD, discusses the risk of ILD and pneumonitis from ADCs.

The Potential Role for HER2-Targeted ADCs in Earlier Treatment Lines

August 1st 2024

Vijayakrishna Gadi, MD, PhD, discusses the role of antibody-drug conjugates in a curative setting.

Overcoming Challenges of Testing for HER2-low Across Solid Tumor Types

August 1st 2024

A panel of experts discuss the challenges of testing for HER2-low access solid tumor types.

ADCs Targeting HER2+ GU Cancers

July 23rd 2024

A panel of experts discuss if there is a role for HER2-directed ADCs antibody-drug conjugates in GU genitourinary cancers

Impact of ADCs on Brain Metastases

July 23rd 2024

A panel of experts discuss where HER2-directed ADCs antibody-drug conjugates fit into the overall treatment paradigm.

ADCs Targeting HER2+ Lung Cancer

July 12th 2024

Dr Garon shares insights on the role of ADCs for the treatment of HER2+ lung cancer.

Emerging Data from ASCO 2024 in HER2-low: DESTINY-Breast06

July 12th 2024

Dr Gadi leads a discussion on recent data on the treatment of HER2-low tumors, including ASCO updates on the DESTINY-Breast06 trial.

ADCs Targeting GI Cancers

July 12th 2024

Dr Parikh discusses the history of ADCs for treating GI cancers with a focus on the data for T-DXd and its role in treating these cancers.

ADCs Targeting HER2+ Gynecologic Cancers

July 12th 2024

Dr Campos discusses the potential for T-DXd in other gynecologic cancers and offers an overview of results from the DESTINY-PanTumor02 trial.

Dr Parikh on Outcomes from the HERKULES-3 Trial in BRAF V600E–Mutant mCRC

June 26th 2024

Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.

ADCs Targeting HER2+ Breast Cancer

June 25th 2024

Dr Gadi introduces treatment and trial data targeting care for patients diagnosed with HER2+ breast cancer.

Assessing HER2 Status Across Tumor Types

June 25th 2024

Dr Gadi leads a discussion surrounding HER2 mutation and overexpression across various cancer types.